| Literature DB >> 26649065 |
Shan Hu1, Yu Chen2, Zhi-Fu Wang3, Qi-Liang Mao-Ying1, Wen-Li Mi1, Jian-Wei Jiang1, Gen-Cheng Wu1, Yan-Qing Wang1.
Abstract
Cancer-induced bone pain (CIBP) is a severe type of chronic pain. It is imperative to explore safe and effective analgesic drugs for CIBP treatment. Baicalein (BE), isolated from the traditional Chinese herbal medicine Scutellaria baicalensis Georgi (or Huang Qin), has been demonstrated to have anti-inflammatory and neuroprotective effects. In this study, we examined the effect of BE on CIBP and the mechanism of this effect. Intrathecal and oral administration of BE at different doses could alleviate the mechanical allodynia in CIBP rats. Intrathecal 100 μg BE could inhibit the production of IL-6 and TNF-α in the spinal cord of CIBP rats. Moreover, intrathecal 100 μg BE could effectively inhibit the activation of p-p38 and p-JNK MAPK signals in CIBP rats. The analgesic effect of BE may be associated with the inhibition of the expression of the inflammatory cytokines IL-6 and TNF-α and through the activation of p-p38 and p-JNK MAPK signals in the spinal cord. These findings suggest that BE is a promising novel analgesic agent for CIBP.Entities:
Year: 2015 PMID: 26649065 PMCID: PMC4662985 DOI: 10.1155/2015/973524
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Intrathecal and oral administration of BE alleviates mechanical allodynia in CIBP. (a) Time course of the development of mechanical allodynia after cancer cell inoculation. Data are expressed as means ± SEM ( p < 0.001 versus the sham group). (b) Intrathecal BE alleviates mechanical allodynia in cancer rats. Data are expressed as means ± SEM ( p < 0.05, p < 0.01 versus cancer + DMSO group). (c) Intrathecal administration of BE has no influence on hind paw withdrawal threshold in naive rats. (d) Oral administration of different doses of BE increased hind paw withdrawal threshold in cancer rats. Data are expressed as means ± SEM ( p < 0.05 and p < 0.01 versus cancer + DMSO group).
Figure 2Intrathecal BE inhibited the expression of proinflammatory factors (IL-6 and TNF-α) in spinal cord of CIBP rats. Intrathecal 100 μg BE markedly downregulated the expression of IL-6 and TNF-α mRNA. Data are presented as means ± SEM ( p < 0.05, p < 0.01, and p < 0.001 versus naïve group; # p < 0.05 and ### p < 0.001 versus cancer + DMSO i.t. group).
Figure 3Intrathecal BE inhibits the expression of p-p38 and p-JNK in spinal cord of CIBP rats. ((a), (b)) Western blot and the quantitative data of p-ERK protein in spinal cord of rats. Protein level of p-ERK significantly increased in CIBP rats compared to naïve rats. However, intrathecal BE (100 μg) had no influence on the expression of p-ERK. ((c), (d)) Western blot and quantitative data of p-p38 protein in spinal cord of rats. Intrathecal BE (100 μg) reduced the expression of p-p38 protein in CIBP. ((e), (f)) Western blot and quantitative data of p-JNK protein in spinal cord of rats. Intrathecal BE (100 μg) reduced the expression of p-JNK in CIBP. ((g), (h)) Western blot and quantitative data of p-STAT3 protein in spinal cord of rats. Intrathecal BE (100 μg) had no influence on the expression of p-STAT3 in CIBP. Data are presented as means ± SEM ( p < 0.05, p < 0.01 versus naïve group; # p < 0.05 versus cancer + DMSO i.t. group).